382 related articles for article (PubMed ID: 33936093)
1.
Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
Front Immunol; 2021; 12():659659. PubMed ID: 33936093
[TBL] [Abstract][Full Text] [Related]
2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
3. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
4. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
5. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
6. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
Su X; Li H; Chen S; Qin C
Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR.
Guo X; Xue H; Shao Q; Wang J; Guo X; Chen X; Zhang J; Xu S; Li T; Zhang P; Gao X; Qiu W; Liu Q; Li G
Oncotarget; 2016 Dec; 7(49):80521-80542. PubMed ID: 27602954
[TBL] [Abstract][Full Text] [Related]
8. Correlation of AIF-1 Expression with Immune and Clinical Features in 1270 Glioma Samples.
Rao M; Yang Z; Huang K; Liu W; Chai Y
J Mol Neurosci; 2022 Feb; 72(2):420-432. PubMed ID: 34939148
[TBL] [Abstract][Full Text] [Related]
9. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
10. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
11. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
12. Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.
Zhu C; Mustafa D; Zheng PP; van der Weiden M; Sacchetti A; Brandt M; Chrifi I; Tempel D; Leenen PJM; Duncker DJ; Cheng C; Kros JM
Neuro Oncol; 2017 May; 19(5):648-659. PubMed ID: 28453746
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.
Liu H; Weng J
Gene; 2022 May; 822():146325. PubMed ID: 35183683
[TBL] [Abstract][Full Text] [Related]
14. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
16.
Huang L; Wang Z; Chang Y; Wang K; Kang X; Huang R; Zhang Y; Chen J; Zeng F; Wu F; Zhao Z; Li G; Huang H; Jiang T; Hu H
Aging (Albany NY); 2020 May; 12(9):8397-8412. PubMed ID: 32396873
[TBL] [Abstract][Full Text] [Related]
17. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
[TBL] [Abstract][Full Text] [Related]
18. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
19. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract][Full Text] [Related]
20. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]